A venture arm of a large pharmaceutical makes equity investments in life science companies, typically in venture rounds. The firm invests at a wide range of product development phases, from preclinical development (up to 18 months away from the first in-human clinical trials) to products that have received regulatory approval, but typically does not invest in products that are on the market. The fund is open to considering investments globally. The firm makes highly varied investments, with a range from $250,000-$19 million.

The firm invests in areas that are strategically important to the parent company in the medical device and diagnostic sectors. The firm’s medical device interests include cardiovascular devices (traditional vascular, endovascular, arterial, venous, fistula formation, BTK, CLI, neurovascular, structural heart, transcatheter, mitral, pulmonary, EP ablation and afibulation, and implantable cardio devices such as pacers and sensors), diabetes devices (including glucose monitors, new sensing technologies, and other insulin management devices such as pumps), neuromodulation devices (primarily spinal cord stimulators and DBS). Within neuromodulation, the firm is interested in all indication areas that can be impacted by the technology. In diagnostics, the firm is focused on molecular diagnostics, core lab diagnostics, point of care diagnostics, and blood bank testing. In point of care diagnostics, the firm is generally only interested in opportunities that offer a broad panel of tests or which are very specific to a certain setting. The firm is also highly interested in diagnostics for traumatic brain injury and concussion. The firm is also interested in imaging technologies and digital technologies that relate to their core areas.

The firm will invest at any stage of development prior to commercialization; the firm may also consider investing in products that are commercialized overseas but not in the USA.

The firm invests only in privately-held companies, but has no other fixed requirements for companies & management teams. As an investor that provides resources and value in addition to capital, the firm may attach some form of rights to investments, but do not use investment structures that will become a hindrance to the portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global pharmaceutical company headquartered in Tokyo, Japan is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, the pharma’s R&D team is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney conditions, and rare diseases. The company is currently looking for partnering and in-licensing opportunities across the globe.

The company is currently looking for innovative therapeutics targeting the following priority areas: oncology, pain management, cardiovascular disease, CNS, and rare diseases. Other interest areas include novel therapeutic targets and approaches for the gut microbiome that can modulate disease outcome, cell therapeutics for serious diseases including Stroke/TIA, PAD/CLI and hepatic cirrhosis, and novel therapies for hematological diseases, especially for anemic disorders with erythropoietin resistance. The company is open to biologics or small molecules, with an increased interest in new platform technologies. The following areas are currently out of focus: diabetes, hypertension, dyslipidemia, psychiatric diseases, and immunodeficiency.

The company partners with privately held life science companies with experienced management teams and innovative technologies in the abovementioned areas.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with over 15 years of experience is looking to invest in tech-based digital health and diagnostics companies looking to expand to the Chinese market. The firm primarily invests in European companies, but will consider companies based in the US as well. The firm looks to leverage their connections to China and the Chinese market on behalf of its portfolio companies. The firm looks to invest between $2-10M in companies, taking a 15-30% equity stake. The firm prefers to be a lead investor, taking an active role in their portfolio companies, and will invest in about 2 companies a year, depending on their fund cycle. In cases where the firm does not invest funds, they are also willing to offer consulting services for equity, connecting companies with strategic partners in China.

The firm has an additional partnership model that, instead of direct investment, licenses technologies through a Chinese platform company, acting as a focused distributor for entry into the Chinese market. This is the firm’s alternate investment approach to bringing these technologies to the Chinese market, by utilizing this Chinese platform company to serve as their portfolio company’s representative in China to navigate the regulatory environment and spearhead all of the sales and marketing.

The firm is interested in tech companies that are not consumer focused. The firm looks for companies such as diagnostics tools or AI/machine learning technologies in the healthcare space. The firm has some experience with pathology diagnostic related companies, but is willing to consider other areas as well. The firm prefers to invest in a few companies within the same area, choosing complementary technologies between their portfolio companies. The firm will consider companies with technologies that are in development or in pilot stages.

The firm is an active investor and takes a board seat for every company in which they invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A large investment firm in Menlo Park, CA, with additional offices throughout the USA and Asia invests broadly in the healthcare and technology sectors, in both venture and growth-stage financing rounds. Due to the firm’s large fund size, the firm generally only invests in rounds that raise $10 million or more. The firm makes investments globally.

Within healthcare, the firm focuses on biopharma, and also invests in medical devices, healthcare IT and healthcare service providers. The firm is generally not seeking opportunities in diagnostics. In biopharma, the firm prefers to invest in companies that have obtained data from human clinical trials; however, the firm also invests in breakthrough therapeutic technologies at the preclinical stage. In medical devices, the firm only invests in growth-stage companies with an approved product and initial revenues; the firm prefers to invest in breakthrough device technologies and avoids commodity markets. The firm has a broad portfolio and is open to any indication area, but has a particular focus in oncology and orphan diseases, and typically does not invest in infectious diseases.

Within the service provision and IT sectors, the firm is focused on opportunities that provide cost savings to the healthcare system; in this sector, the firm’s expertise is primarily in companies that target healthcare providers as customers, but the firm is also open to considering other areas of the services/IT space. The firm has no fixed requirements for companies or management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global chemical company has established a successful USA office that has grown to become the corporation’s main sales, marketing, and business development center in North America. In addition to a variety of other markets, the group serves the chemical, petrochemical and bioscience markets. The group has recently started a corporate venture initiative with a $300M budget to make strategic investments into both pre and post-commercial companies. The group is flexible in terms of structuring investments and may employ equity investments, M&A and licensing agreements. The group targets investment sizes from $100k – $5M for early stage companies and $10M-$50M for commercial-stage companies.

In terms of the healthcare and life science sectors, the group is most interested in companies working in diagnostics and research tools. The group is particularly interested in clinical diagnostics including IVDs and next generation platforms (NGS, liquid biopsy, LC-MS, point-of-care testing, digital PCR), separation media and connected devices and wearable medical sensors. The group is also interested in advanced materials including materials for secondary batteries, thin-film for electronic devices, separation (inorganic/organic/polymers) and composites. The group is agnostic to indication area, but has a particular interest in cancer, metabolic (including diabetes) and kidney disorders as well as reproductive health.

The group has no strict company or management team requirements and invest in both early and later stage opportunities. Board observer status is required along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A China-focused investment firm based in Shanghai seeks to invest in emerging Medical Technology and Diagnostics companies at near commercial or commercial stage. The investments are typically in forms of equity. The investment size generally ranges from US$2 million to US$10 million. The firm primarily invests in companies across China, but it will also consider Medical Devices that have attained approval to enter the market in China.

The firm is currently looking for new opportunities in the Medical Technology and Diagnostics sectors. The firm is open to all classes of medical devices and it is opportunistic in terms of indications. The firm is particularly interested in companies with products that are completing or have already completed China regulatory approvals and are preparing to enter the Chinese market. It is also interested in companies with products already on the market. The firm focuses on the phase of development more than the products.

The firm generally invests in private companies with a strong management team and significant growth potential. The firm will consider make PIPE investments on a case-by-case basis. The firm looks to take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment firm based in the East Coast builds and invests in companies in the healthcare sector, with a focus on personalized health and consumer health. The firm typically invests in seed or Series A rounds and initial investments range from $150,000-$1.5 million, with a potential commitment of up to $5 million over the life of the investment. The firm invests in the USA and Canada.

The firm focuses on healthtech and tech-enabled health services. The firm is interested in disease management (includes chronic, autoimmune, mental/behavioral, neurology, microbiome, and digital therapeutics), care management, precision medicine, remote monitoring (including pushing the point of care into ambulatory settings such as retail clinics and the home), population health management (including underserved patients and Medicaid recipients, and patients living in areas outside the East Coast and West Coast). The firm is also open to investing in devices and diagnostics, but only if they are targeted at consumers/patients as users, rather than physicians.

The firm generally does not invest in companies that face FDA regulatory risk; the firm invests in companies with products that are already approved or do not require FDA approval. The firm prefers to invest in revenue generating companies but will consider startups that will begin to generate revenue in 6-12 months.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.